Charles M. Conway

Statistics

Publications

Citations

2.1K

H-Index

Active since

1997

Affiliations

Bristol-Myers Squibb (United States)(Current)

Biohaven Pharmaceuticals (United States)

Albert Einstein College of Medicine

California Medical Clinic for Headache

King's College Hospital

Charles M. Conway is an author at Bristol-Myers Squibb (United States) specializing in pharmacology, calcitonin gene-related peptide antagonists, and pharmacy.

Publications per year

1997–2022

Publications

Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine

Richard B. Lipton, Robert Croop, Elyse Stock et al. · New England Journal of Medicine · 2019 · 396 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14

Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial

Robert Croop, Peter J. Goadsby, David Stock et al. · The Lancet · 2019 · 392 citations

Pharmacy, Pharmacology, Pharmacotherapy +12

Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial

Robert Croop, Richard B. Lipton, David Kudrow et al. · The Lancet · 2020 · 351 citations

Pharmacy, Neurology, Pharmacotherapy +12

The Acute Antihyperalgesic Action of Nonsteroidal, Anti-Inflammatory Drugs and Release of Spinal Prostaglandin E<sub>2</sub>Is Mediated by the Inhibition of Constitutive Spinal Cyclooxygenase-2 (COX-2) but not COX-1

Tony L. Yaksh, David M. Dirig, Charles M. Conway et al. · Journal of Neuroscience · 2001 · 269 citations · Full text

Medicine, Pharmacology, Biochemical Pharmacology +14

Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine

Gary Berman, Robert Croop, David Kudrow et al. · Headache The Journal of Head and Face Pain · 2020 · 101 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

1–5 of 27